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Abstract
What’s known on the subject? and What does the study add?
To the best of our knowledge, this is the first study that validates renal cell carcinoma 2010 tumor-node-metastasis for the Turkish population.
Objective: The American Joint Committee on Cancer tumor-node-metastasis (TNM) classification has been updated by the 7th edition in 2010. The 
objective of the study was to evaluate cancer-specific survival (CSS) in patients with renal cell carcinoma (RCC) and assess the concordance of 2002 
and novel 2010 TNM primary tumor classifications. 
Materials and Methods: A retrospective analysis of RCC registries from 25 institutions of the Urooncology Association of Turkey Renal Cancer-
Study Group was performed. Patients with RCC had a radical or partial nephrectomy. The database consisted of 1889 patients. 
Results: Median follow-up time was 25 months (interquartile range: 11.2-47.8). The 5-year CSS rate for pT1a, pT1b, pT2a, pT2b, pT3a and pT4 tumors 
were 97% [95% confidence interval (CI): 0.93-0.99], 94% (95% CI: 0.91-0.97), 88% (95% CI: 0.81-0.93), 77% (95% CI: 0.64-0.86) 74% (95% CI: 
0.65-0.81) and 66% (95% CI: 0.51-0.77), respectively according to the 2010 TNM classification (p<0.001). CSS comparisons between pT1a-pT1b 
(p=0.022), pT1b-pT2a (p=0.030), pT3a-pT3b (p<0.001) and pT3b-pT4 (p=0.020) were statistically significant. Conversely, pT2a-pT2b (p=0.070) and 
pT2b-pT3a (p=0.314) were not statistically significant. Multivariable analyses revealed the pT stage in the 2010 TNM classification as an independent 
prognostic factor for CSS (p for trend=0.002). C-indexes for 2002 and 2010 TNM classifications were 0.8683 and 0.8706, respectively. 
Conclusion: Subdividing pT2 does not have a CSS advantage. Moving adrenal involvement to pT4 yielded a more accurate prognosis prediction. T 
stage and LNI are independent prognostic factors for CSS in RCC. Overall, the novel 2010 TNM classification is slightly improved over the former one. 
However, shown by C-index values, this improvement is not sufficient to state that 2010 TNM outperforms the 2002 TNM.
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Introduction
The tumor-node-metastasis (TNM) primary tumor staging 
classification is an internationally accepted and widely used 
tool to determine the anatomical extent of cancer spread. TNM 
classification system categorizes tumors on the basis of primary 
tumor characteristics (T), the presence or absence of regional 
lymph node involvement (LNI) (N), and the presence or absence 
of distant metastases (M) including non-regional LNIs. It is an 
essential part of the reports for the assessment of the prognosis 
of malignancies.
The major changes in renal cell carcinoma (RCC) in the 2010 
American Joint Committee on Cancer TNM (7th edition) with 
respect to 2002 version were re-classification of ipsilateral 
adrenal involvement from pT3a to pT4, and renal vein 
involvement (RVI) from pT3b to pT3a. Also, pT2 tumors were 
subdivided into tumors greater than 7 cm and less than 10 cm 
into pT2a and tumor limited to kidney and greater than 10 cm 
into pT2b groups (1). LNI was simplified as yes or no regardless 
of a single or multiple LNI as in 2002 version.
The objective of the present study was to evaluate cancer-
specific survival (CSS) in RCC patients operated by the surgeons 
member of the Urooncology Association of Turkey Renal 
Cancer-Study Group (UATRC-SG) and assess the concordance of 
2002 and novel 2010 TNM primary tumor classifications. 
Materials and Methods
A retrospective analysis of RCC registries from 25 member 
institutions of the UATRC-SG was performed. These centers 
contributed with their data from all patients who underwent 
radical or partial nephrectomy between 1987 and 2007 for 
kidney tumors and had no evidence of metastasis at the time of 
surgery. Decision, either for partial or radical nephrectomy was 
made on the discretion of the operating surgeon.
A total of 1889 patients had been operated and 198 of them 
underwent partial nephrectomy. Patients with von Hippel-
Lindau disease and synchronous bilateral tumors were not 
included in the database. Collected data from all centers were 
pooled in a single database. For the purposes of this study, the 
contents of the data consisted of patients’ date of birth, gender, 
presence of systemic symptom, presentation, surgical approach, 
pathological size, perinephric fat invasion (PNI), RVI, adrenal 
invasion, invasion beyond Gerota’s fascia, LNI, pathological T and 
N stage (2002 TNM), Fuhrman nuclear grade, histological tumor 
type, adjuvant treatment, recurrence, vital status, date of death, 
cause of death, and date of last follow-up parameters. The data 
was originally recorded with 2002 TNM classification. For the 
purposes of this study, patients’ pT stages were re-assigned into 
2010 TNM stage. Consequently, the database consisted of 1889 
patients.
Five centers submitted more than 100 patients, 11 submitted 50 
to 100, and 9 submitted less than 50 patients. Overall, 45.05% 
(n=851) of patients were submitted by 5 centers that provided 
data on more than 100 cases. The number of patients operated 
before 1997, between 1997 and 2002, and after 2002 were 82 
(4.34%), 389 (20.59%) and 1418 (75.07%), respectively (Table 
1). Patients from all centers were included regardless of the 
participant center’s patient volume in this study.
Apart from minor differences in clinical practice, common 
follow-up protocol included physical examination, serum 
blood urea nitrogen and creatinine determination, chest and 
abdominal computed tomography scanning every 6 months for 
2 years and annually thereafter.
The underlying cause of death was obtained from death 
certificates and medical records. In the absence of any of these, 
telephone conversation with patients’ relatives was used to 
determine the time and cause of death.
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Öz
Amaç: Amerikan Kanser Ortak Komitesi tümör-nod-metastaz (TNM) tümör sınıflaması 7. basım ile güncellendi. Bu çalışmada böbrek hücreli karsinom 
(BHK) 2002 ve 2010 TNM sınıflamaları kansere özgü sağkalım (KÖS) açısından değerlendirildi. 
Gereç ve Yöntem: Üroonkoloji Derneği Böbrek Kanseri Çalışma Grubu üyesi 25 merkezin radikal veya parsiyel nefrektomi yapılmış BHK hasta 
kayıtları geriye dönük olarak değerlendirildi. Çalışmaya 1889 hasta dahil edildi. 
Bulgular: Hastaların ortanca takip süresi 25 ay (çeyrek değerler genişliği: 11,2-47,8) idi. TNM 2010’a göre 5 yıllık KÖS pT1a’da %97 [%95 güven 
aralığı (GA): 0,93-0,99], pT1b’de %94 (%95 GA: 0,91-0,97), pT2a’da %88 (%95 GA: 0,81-0,93), pT2b’de %77 (%95 GA: 0,64-0,86), pT3a’da %74 
(%95 GA: 0,65-0,81) ve pT4’te %66 (%95  : 0,51-0,77) olarak saptandı (log-rank p<0,001). pT grupları arası ikili karşılaştırma pT1a-pT1b (p=0,022), 
pT1b-pT2a (p=0,030), pT3a-pT3b (p<0,001) ve pT3b-pT4 (p=0,020) arasında istatistiksel olarak anlamlı idi. Ancak pT2a-pT2b ve pT2b-pT3a (p>0,05) 
istatistiksel olarak anlamlı değildi. Tek değişkenli ve çok değişkenli analizlerde pT evresi 2010 TNM evresi bağımsız prognostik faktör olarak saptandı 
(p for trend=0,002). TNM 2002 için C-indeks=0,8683 ve TNM 2010 için c-indeks=0,8706 olarak saptandı. 
Sonuç: pT2’yi pT2a ve pT2b olarak ayırmak KÖS açısından avantaj sağlamamaktadır. Adrenal invazyonunu pT4’e taşımak daha doğru bir prognoz 
öngörüsü sağladı. BHK’de lenf nodu tutulumu ve pT evresi KÖS için bağımsız prognostik faktördür. TNM 2010 C-indeks sonuçlarına göre KÖS için 
TNM 2002 sınıflamasından daha üstün değildir. 
Anahtar Kelimeler: Böbrek hücreli kanser, böbrek kanseri, 2010 tümör-nod-metastaz, primer tümör sınıflaması
55
Özkan et al. 
2010 Tumor-Node-Metastasis for Renal Cell Carcinoma
Journal of Urological Surgery, 
2017;4:53-60
Statistical Analysis
The results were expressed as means ± standard deviation and 
median [interquartile range (IQR)]. All evaluated variables 
except for age and pathological tumor size were categorical. 
Patients were censored at the time of death for other reasons 
or last follow-up. Patients were considered as failed if they died 
of RCC. Survival probability was estimated using the Kaplan-
Meier method. Log-rank test was used to compare CSS between 
the groups. CSS was calculated for median survival time and 
5-year survival. Trend test was constructed using the log-rank 
test. Concordance index was used to further compare the 
predictive ability of the 2002 and 2010 TNM classifications (2). 
Univariable and multivariable analyses were performed with 
Cox proportional hazards regression model and 95% confidence 
intervals (CIs) were calculated. All analyses were performed 
using STATA 12.0 statistical software package (Stata Corp, Texas, 
USA). Statistical significance was set at 0.05 and all tests were 
two-tailed.
Results 
A total of 1889 patients operated for RCC were included in this 
study. Clinical and pathological features of these patients are 
summarized in Table 2. Median follow-up time was 25 months 
(IQR: 11.2-47.8) for the whole cohort and 25.4 months (IQR: 
11.8-48.8) for the surviving patients. Of all, 151 (8%) patients 
died from RCC at a median follow-up of 20.4 months (IQR: 
7.1-36) and 73 (3.9%) died from other causes. Seven hundred 
eighty-two patients (41.4%) who were alive at last follow-up 
had fewer than 24 months of follow-up. Death due to disease 
was observed in 79.5% of the patients (120/151) with in the 
first 2 years. A total of 311 patients (16.5%) had been followed 
for more than 60 months. Recurrent disease was seen in 208 
patients (13.7%). Adjuvant treatment was given to 106 patients 
(9.9%). 
The 2-year CSS rates for pT1a, pT1b, pT2a, pT2b, pT3a, pT3b 
and pT4 tumors were 98% (95% CI: 0.95-0.99), 96% (95% CI: 
0.93-0.98), 88% (95% CI: 0.81-0.93), 81% (95% CI: 0.70-0.88), 
79% (95% CI: 0.71-0.84), 46% (95% CI: 0.23-0.67), and 68% 
(95% CI: 0.54-0.79), respectively according to the 2010 TNM 
classification. The respective 5-year CSS rates for pT1a, pT1b, 
pT2, pT3a, pT3b and pT4 tumors were 98% (95% CI: 0.94-0.99), 
96% (95% CI: 0.92-0.98), 89% (95% CI: 0.83-0.93), 89% (95% 
CI: 0.80-0.94) 64% (95% CI: 0.36-0.83) and 75% (95% CI: 0.54-
0.88), according to the 2002 TNM classification. The respective 
5-year CSS rates for pT1a, pT1b, pT2a, pT2b, pT3a and pT4 
tumors were 97% (95% CI: 0.93-0.99), 94% (95% CI: 0.91-0.97), 
88% (95% CI: 0.81-0.93), 77% (95% CI: 0.64-0.86) 74% (95% 
CI: 0.65-0.81) and 66% (95% CI: 0.51-0.77), according to the 
2010 TNM classification (log-rank p<0.001, Figure 1). No CSS 
outcome was provided for pT3b stage group at 5 years since 
there was no patient followed up for more than 52 months in 
the group. No patient was registered for stage pT3c disease. 
Pairwise CSS comparisons for consecutive T stages according to 
2010 TNM classification between pT1a-pT1b (p=0.022), pT1b-
pT2a (p=0.030), pT3a-pT3b (p<0.001) and pT3b-pT4 (p=0.020) 
were statistically significant. However, pairwise comparisons 
between pT2a-pT2b (p=0.070) and pT2b-pT3a (p=0.314) were 
not statistically significant. When 1761 patients without LNI 
Figure 1. Cancer-specific survival probability according to 2002 (a) and 2010 (b) tumor-node-metastasis classification 
TNM: Tumor-node-metastasis, CSS: Cancer-specific survival
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were considered, only pairwise CSS comparison between pT1a 
and pT1b (p=0.009) was statistically significant. 
When pT3a was substratified/subdivided according to PNI and 
RVI, 246 cases had PNI only (76.4%), 30 RVI only (9.3%) and 46 
patients (14.3%) had both. Pairwise CSS comparisons of RVI vs. 
PNI [hazard ratio (HR): 4.35 95% CI: 0.59-31.8 p=0.147] and 
PNI vs. RVI + PNI (HR: 1.96 95% CI: 0.9-4.1 p=0.072), failed to 
disclose statistically significant difference (Figure 2). However, 
RVI only group had statistically significantly better CSS than 
RVI + PNI group (HR: 8.52 95% CI: 1.1-67.6 p=0.043). When 
lymph node-positive 38 patients were excluded, CSS differences 
between all subgroups were not statistically significant (data 
not shown). 
The pT3b category consisted of 40 patients and 20 (50%) had 
infradiaphragmatic vena cava involvement (IVCI) only. Both PNI 
and IVCI were present in 20 patients (50%). Patients who had 
PNI + IVCI had poorer CSS compared to IVCI only patients (HR: 
4.98 95% CI: 1.1-22.6 p=0.015). When 8 lymph node-positive 
patients were excluded, this statistically significant difference 
was lost (p=0.089).
A total of 121 patients were in the pT4 category. Forty-eight 
patients had invasion beyond Gerota’s fascia and 73 patients 
had ipsilateral continuous adrenal invasion. No statistically 
significant difference was noted in CSS between Gerota’s fascia 
invasion and adrenal invasion subgroups (HR: 1.14 p=0.75). 
When lymph node-positive patients were excluded, analysis on 
a total of 41 patients also resulted in non-significant difference 
(p=0.73).
On the univariable Cox regression analysis, age, gender, mode 
of presentation, type of surgery, histological tumor type, tumor 
size, pT stage, lymph node invasion, and Fuhrman nuclear grade 
all emerged as significant prognostic factors for CSS (Table 
3). On the univariable analyses for 2002 and 2010 TNM pT 
stage, C-indexes were 0.7626 (p<0.001) and 0.7694 (p<0.001), 
respectively. pT stage classifications in both 2002 and 2010 TNM 
staging systems resulted in statistically significant CSS prediction 
and c-index improved in the novel 2010 TNM classification. 
When patients with LNI excluded from the analysis 2002 and 
2010 TNM pT stage remained statistically significant (p<0.001), 
C-indexes were 0.7463 and 0.7516, respectively.
On the multivariable analyses, age, type of surgery, and tumor 
size were not independent prognostic factors and were excluded 
from the final model. When controlled with all other covariates 
(gender, presentation, histological tumor type, Fuhrman grade, 
pathological tumor size, T and N stage) in the multivariable 
analyses, the pT stage in the 2010 TNM classification was an 
Table 1. Number of patients’ distribution among participated 
centers
Participated center n %
Ankara Training and Research Hospital 36 1.91
Ankara Numune Training and Research Hospital 70 3.71
Ankara University Faculty of Medicine 392 20.75
Atatürk Training and Research Hospital 15 0.79
Başkent University Adana Hospital 62 3.28
Başkent University Faculty of Medicine 116 6.14
Celal Bayar University Faculty of Medicine 26 1.38
Çukurova University Faculty of Medicine 34 1.80
Cumhuriyet University Faculty of Medicine 32 1.69
Dicle University Faculty of Medicine 25 1.32
Ege University Faculty of Medicine 98 5.19
Erciyes University Faculty of Medicine 93 4.92
Göztepe Training and Research Hospital 64 3.39
Hacettepe University Faculty of Medicine 101 5.35
Haydarpaşa Sultan Abdülhamid Training and 
Research Hospital
80 4.24
Haydarpaşa Numune Training and Research 
Hospital
62 3.28
İnönü University Faculty of Medicine 34 1.80
Kartal Training and Research Hospital, 1st 
Department of Urology
34 1.80
Kartal Training and Research Hospital, 2nd 
Department of Urology
17 0.90
Kocaeli University Faculty of Medicine 58 3.07
Marmara University Faculty of Medicine 110 5.82
Mersin University Faculty of Medicine 7 0.37
Ondokuz Mayıs University Faculty of Medicine 55 2.91
Osmangazi University Faculty of Medicine 99 5.24
Tepecik Training and Research Hospital 132 6.99
Trakya University Faculty of Medicine 37 1.96
Total 1.889 100
Figure 2. Cancer-specific survival probability for pT3a according to renal 
vein and/or perinephric involvement
RVI: Renal vein involvement, PNI: Perinephric fat invasion, CSS: Cancer-specific survival
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independent prognostic factor for CSS (p for trend=0.002) 
(Table 3). However, when pT1a stage was used as a reference, 
pT1b stage was not an independent prognostic factor (HR: 
1.9 p=0.211). In the final model, C-indexes for 2002 and 2010 
TNM classifications were 0.8683 and 0.8706, respectively. When 
only 1731 N0 patients were considered, the pT stage retained 
its significance as an independent prognostic factor (p for 
trend=0.011). 
Discussion
Prediction of CSS is one of the main issues for malignant diseases. 
The TNM primary tumor classification system is a widely used, 
validated tool for this purpose (3). This classification system 
is a common ground for evaluating the anatomical extent of 
malignancies. 
In the present study, analysis revealed that some of the changes 
made between T stages in 2010 TNM classification improved 
prediction of CSS for RCC. 
The change in pT2 stage in 2010 TNM classification is a topic 
still under debate. This change was based on a single study 
(4). In this study, results of 544 patients were evaluated and 
a 10 cm cut-off point was assigned for the subdivision of pT2 
patients into pT2a and pT2b. However, other studies did not 
support a 10 cm cut-off for pT2 group (5,6,7,8). In a detailed 
analysis of pT2 group, Brookman-May et al. (5) reported that 
neither a cut-off value of 10 cm nor alternative cut-off values 
(8, 9, 11, 12, 13 cm) had an impact on CSS. In another study, a 
cut-off value of 11 cm was offered for the subdivision of pT2a 
and b (9). It is argued that tumor aggressiveness features, as 
collecting system invasion in one study, may be more important 
than tumor size alone in the determination of prognosis (5). The 
present study also revealed no statistically significant difference 
in CSS between 2010 pT2a and pT2b TNM stages, similar to the 
other previously reported series (5,6,7,8). Additionally, T2b-T3a 
patients had similar prognosis in the present study cohort. This 
may be due to the small number of patients with fewer failures 
in T2b group. 
In 2005, Thompson et al. (10) reported that in the 2002 TNM 
classification, pT3a patients had unfavorable prognosis because 
of ipsilateral adrenal involvement when compared with pT3a 
patients with PNI only. In addition, prognosis in these patients 
with adrenal involvement was similar to that in pT4 group. 
Based on this data, patients with ipsilateral adrenal involvement 
were placed into pT4 group in the 2010 TNM classification. In 
the same study in pT3b group, patients with PNI died twice as 
likely as not PNI cases. Based on this observation concerning 
PNI status and level of tumor thrombus, a new classification for 
pT3 patients was offered (10) as follows: pT3a (RVI only), pT3b 
(PNI only), pT3c (PNI or IVCI), and pT3d (PNI + IVCI or VCI above 
Table 2. Clinical and pathological characteristics of the 
patients (n=1889)
Age, years, median (IQR)  57 (48-65)
Gender, no (%)
Male
Female
1178 (62.4)
711 (37.6)
Presentation, no (%)
Incidental 
Local symptoms
Systemic symptoms
821 (43.5)
821 (43.5)
247 (13.1)
Type of surgery, no (%)
Radical nephrectomy
Partial nephrectomy
1691 (89.5)
198 (10.5)
Histological tumor type†, no (%)
Clear cell
Papillary
Chromophobe
Collecting duct
Unclassified
1431 (80.7)
185 (10.4)
138 (7.8)
12 (0.7)
8 (0.4)
Fuhrman nuclear grade‡, no (%)
Grade I
Grade II
Grade III
Grade IV
212 (13.2)
883 (54.9)
409 (25.4)
105 (6.5)
Pathological tumor size, mm, median (IQR) 60 (40-85)
Pathological T stage (2002 TNM), no (%)
T1a
T1b
T2
T3a
T3b
T3c
T4
460 (24.4)
565 (29.9)
381 (20.2)
282 (14.9)
134 (7.1)
0
67 (3.5)
Pathological T stage (2010 TNM), no (%)
T1a
T1b
T2a
T2b
T3a
T3b
T3c
T4
460 (24.4)
565 (29.9)
242 (12.8)
139 (7.4)
322 (17)
40 (2.1)
0
121 (6.4)
Pathologic N stage (2010 TNM), no (%)
Nx
N0
N1
8 (0.4)
1761 (93.2)
120 (6.4)
†Missing in 115 patients
‡Missing in 290 patients
IQR: Interquartile range, TNM: Tumor-node-metastasis
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diaphragm). In another study, the novel 2010 TNM classification 
was validated (11). In this study, pT3a patients were subdivided 
as (a) PNI invasion only, (b) RVI only, and (c) PNI + RVI. RVI 
only group had the most favorable outcome, followed by 
PNI and, RVI + PNI had the worst CSS. Furthermore, patients 
with pT3b disease were subdivided into IVCI and PNI + IVCI 
subgroups, where PNI + IVCI had significantly worse CSS than 
IVCI alone (11). In the present study, the cohort had different 
characteristics unlike in the previously stated studies for 2010 
pT3a group. Approximately 80% of the patients had only PNI. 
In the pT3b group, distribution of PNI only and PNI + IVCI were 
equal. Patients with IVCI had statistically significantly better 
CSS than IVCI + PNI group. When lymph node-positive patients 
were excluded, these statistically significant CSS differences 
disappeared in both pT3a and pT3b groups. This is mainly due 
to the fact that overwhelming majority (72%) of the patients 
with LNI also had advanced pT stages (pT3-4). The LNI was also 
an independent prognostic factor (Table 3). PNI with IVCI or RVI 
has a poor prognosis. On the other hand, PNI only and RVI only 
patients have similar prognostic outcomes (Figure 2). In this 
regard, simultaneous extension into two different anatomical 
sites (PNI and RVI or IVCI) appears to trigger a rapid progression 
in disease. Our results confirmed that PNI + IVCI or PNI +RVI 
worsened the prognosis in TNM 2010 pT3a and pT3b subgroups 
Table 3. Univariable and multivariable Cox regression analyses of cancer-specific mortality
Variables Univariable Multivariable
HR (95% CI) p HR (95% CI) p
Gender
Male
Female
1 reference
0.56 (0.39-0.81)
-
0.002
1 reference
0.63 (0.412-0.967)
-
0.034
Presentation
Incidental 
Local symptoms
Systemic symptoms
1 reference
2.02 (1.36-3.0)
5.0 (3.26-7.66)
-
0.001
0.000
1 reference
1.97 (1.21-3.21)
3.80 (2.25-6.42)
-
0.007
0.000
Histological tumor type
Clear cell
Papillary
Chromophobe
Collecting duct
Unclassified
1 reference
0.86 (0.50-1.50)
0.17 (0.04-0.68)
8.53 (3.12-23.33)
8.02 (2.54-25.32)
-
0.601
0.012
0.000
0.000
1 reference
1.11 (0.62-2.02)
0.49 (0.12-2.05)
0.73 (0.20-2.71)
3.13 (0.89-11.0)
-
0.721
0.334
0.642
0.075
Fuhrman nuclear grade
Grade I
Grade II
Grade III
Grade IV
1 reference
1.75 (0.68-4.48)
7.55 (3.04-18.79)
18.35 (6.98-48.24)
-
0.242
0.000
0.000
1 reference
1.61 (0.45-3.0)
3.95 (1.57-9.98)
3.74 (1.34-10.4)
-
0.758
0.004
0.012
Pathological tumor size‡, cm 1.01 (1.01-1.02) 0.000 1.00 (0.99-1.00) 0.698
Pathological T stage 
T1a
T1b
T2a
T2b
T3a
T3b
T3c‡
T4
1 reference
2.88 (1.17-7.10) 
5.80 (2.28-14.70)
10.66 (4.25-26.74)
14.05 (6.01-32.87)
48.52 (18.32-128.50)
-
21.73 (8.94-52.82)
-
0.022
0.000
0.000
0.000
0.000
-
0.000
1 reference
1.93 (0.69-5.41)
3.28 (1.10-9.78)
5.63 (1.74-18.19)
6.64 (2.44-18.03)
14.26 (4.40-46.3)
-
6.35 (2.13-19.0)
-
0.211
0.033
0.004
0.000
0.000
-
0.001
Pathologic N stage
N0
N1
1 reference
9.16 (6.39-13.12)
-
0.000
1 reference
3.65 (2.32-5.72)
-
0.000
†Calculated as continues variable
‡No patients
HR: Hazard ratio, CI: Confidence interval
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(10,11). In this context, relative influence of PNI on RVI and IVCI 
should be seriously considered in the subdivision of pT3a and 
pT3b groups in the new versions of the TNM classification. 
CSS comparison between pT3b and pT4 was statically significant 
in favor of pT4. The Kaplan-Meier survival estimates showed 
a steep decrease in pT3b group during the initial 30-month 
follow-up period (Figure 1). This may be a consequence of small 
number of patients (n=40) and some patients in pT3b group 
with minute vena cava wall invasion may be overlooked and 
classified as pT3b rather than pT3c. These results were also 
evident by wide CIs for both pT3b and pT4 groups. Considering 
the results of the other T stage groups, in adequate number of 
patients for both pT3b and pT4 groups, similar results may be 
obtained.
In the present study, we did not have any patients operated 
with tumor thrombus invading the vena cava above diaphragm 
or invading the wall of the vena cava. This is similar to the 
other RCC series in which patients classified in pT3c group also 
constitute a very small percentage ranging from 0.5% to 0.6% 
(7,8,11,12).
Study Limitations
The present study has some important limitations. The most 
important limitation is its retrospective design. The results from 
25 institutions lead to heterogeneity in preoperative work-up, 
surgical practice and post-operative follow-up. Other limitations 
were short follow-up period, lack of central pathological review, 
small number of pT3b and lack of pT3c patients. Concern 
about our short follow-up time can be alleviated by the fact 
that although follow-up time is median 25 months, 79.5% of 
patients died from RCC before the 24th months of follow-up. 
Renal sinus fat invasion was not included in the present study, 
as most of the pathology reports had not mentioned this status.
Conclusion
Both univariable and multivariable analyses revealed that the 
2010 TNM classification had an independent prognostic value. 
When compared with the 2002 TNM classification, novel 2010 
TNM classification slightly improved prognostic accuracy 
(11,13). Ease of use, accumulated knowledge, and wide spread 
use of TNM primary staging systems maintain its contribution 
to other predictive models (14,15).
The impact of recent targeted therapy agents on long-term 
prognosis is yet to be seen. In this regard, staging will continue 
to evolve in observance of the results with the use of these 
targeted agents. 
Subdividing pT2 into pT2a and pT2b in the 2010 TNM classification 
does not have a CSS advantage. Moving ipsilateral adrenal 
involvement patients from pT3a to pT4 yielded a more accurate 
prognosis prediction in both pT3a and pT4 groups. T stage and LNI 
are independent prognostic factors for CSS in RCC. 
Overall, the Turkish multi-institutional experience revealed 
that novel 2010 TNM classification is slightly improved over 
the former one. However, shown by C-index values, this 
improvement is not sufficient to state that the 2010 TNM 
outperforms the 2002 TNM.
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